Fernando Javier Lavalle-González

Dr. Fernando Javier Lavalle-González

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2013 in Diabetologia
Verified
Journal Article
Open access
PDF file
FLFernando Javier Lavalle-González
Fernando Javier Lavalle-González
AJA. Januszewicz
A. Januszewicz
JDJ. Davidson
J. Davidson
CTC. Tong
C. Tong
RQR. Qiu
R. Qiu
GMG. Meininger
G. Meininger
Aims/hypothesis The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being treated with background metformin. Methods This randomised, double-blind, four-arm, parallel-group, Phase 3 study was conducted at 169 centres in 22 countries between April 2010 and August 2012. Participants (N = 1,284) with type 2 diabetes aged ≥18 and ≤80 years who had inadequate glycaemic control (HbA1c ≥7.0% [53 mmol/mol] and ≤10.5% [91 mmol/mol]) on metformin therapy received canagliflozin 100 mg or 300 mg, sitagliptin 100 mg, or placebo (n = 368, 367, 366, 183, respectively) for a 26 week, placebo- and active-controlled period followed by a 26 week, active-controlled period (placebo group switched to sitagliptin [placebo/sitagliptin]) and were included in the modified intent-to-treat analysis set. Randomisation was performed using a computer-generated schedule; participants, study centres and the sponsor were blinded to group assignment. The primary endpoint was change from baseline in HbA1c at week 26; secondary endpoints included changes in HbA1c (week 52) and fasting plasma glucose (FPG), body weight, and systolic blood pressure (BP; weeks 26 and 52). Adverse events (AEs) were recorded throughout the study. Results At week 26, canagliflozin 100 mg and 300 mg reduced HbA1c vs placebo (−0.79%, –0.94%, –0.17%, respectively; p < 0.001). At week 52, canagliflozin 100 mg and 300 mg demonstrated non-inferiority, and canagliflozin 300 mg demonstrated statistical superiority, to sitagliptin in lowering HbA1c (−0.73%, –0.88%,–0.73%, respectively); differences (95% CI) vs sitagliptin were 0% (−0.12, 0.12) and −0.15% (−0.27, –0.03), respectively. Canagliflozin 100 mg and 300 mg reduced body weight vs placebo (week 26: –3.7%, –4.2%, –1.2%, respectively; p < 0.001) and sitagliptin (week 52: –3.8%, –4.2%, –1.3%, respectively; p < 0.001). Both canagliflozin doses reduced FPG and systolic BP vs placebo (week 26) and sitagliptin (week 52) (p < 0.001). Overall AE and AE-related discontinuation rates were generally similar across groups, but higher with canagliflozin 100 mg. Genital mycotic infection and osmotic diuresis-related AE rates were higher with canagliflozin; few led to discontinuations. Hypoglycaemia incidence was higher with canagliflozin. Conclusions/interpretation Canagliflozin improved glycaemia and reduced body weight vs placebo (week 26) and sitagliptin (week 52) and was generally well tolerated in patients with type 2 diabetes on metformin. Clinical trial registry ClinicalTrials.gov NCT01106677 Funding This study was supported by Janssen Research & Development, LLC.

1 March 2012 in Annals of Hepatology
Verified
Journal Article
Open access
DGDiego García-Compeán
Diego García-Compeán
JJJoel Omar Jáquez-Quintana
Joel Omar Jáquez-Quintana
FLFernando Javier Lavalle-González
Fernando Javier Lavalle-González
ERErick Reyes-Cabello
Erick Reyes-Cabello
JGJosé Alberto González-González
José Alberto González-González
HMHéctor J. Maldonado-Garza
Héctor J. Maldonado-Garza
To define the prevalence and clinical characteristics of glucose metabolism disorders (GMD) in patients with compensated liver cirrhosis (LC). Fasting plasma glucose (FPG) levels were measured to 130 patients with clinically stable LC. Oral glucose tolerance tests (OGTT) and fasting plasma insulin determinations were performed to patients with normal FPG. Insulin resistance (IR) was calculated with HOMA2-IR index. GMD were classified according to FPG and OGTT tests results and to the chronologic relation between diagnosis of diabetes mellitus (DM) and LC as follows: type-2 DM (T2DM), hepatogenous diabetes (HD) and impaired glucose tolerance. Patients from all groups were compared. The prevalence of GMD were as follows: T2DM in 25 patients (19.2%, 95% CI 12.5-25.9), HD in 28 (21.5%, 95% CI 14.5-28.5) and IGT in 36 (38.5%, 95% CI 30.1-46.7). The total of patients with GMD was 79.2% (95% CI 72.3-86.1). In 41% of cases GMD were subclinical and 48.7% of patients had IR. Patients with T2DM had a higher number of variables with significant differences compared with the other groups (more marked compared to the patients without GMD). The only differences between the patients with T2DM and HD were hypercreatininemia: 1.14 ± 0.53 vs. 0.84 ± 0.22 mg/dL (p = 0.005) and family history of DM: 8 (32%) vs. 2 (7%) (p = 0.02). Almost 80% of patients with compensated LC had GMD. Half of them were subclinical. The patients with T2DM had marked clinical differences compared to patients from the other groups, particularly renal impairment.

4 April 2013 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
JGJose Gerardo Gonzalez-Gonzalez
Jose Gerardo Gonzalez-Gonzalez
LMLeonor Guadalupe Mireles-Zavala
Leonor Guadalupe Mireles-Zavala
RRRene Rodriguez-Gutierrez
Rene Rodriguez-Gutierrez
DGDavid Gomez-Almaguer
David Gomez-Almaguer
FLFernando Javier Lavalle-González
Fernando Javier Lavalle-González
JPJesús Zacarías Villarreal Pérez
Jesús Zacarías Villarreal Pérez
Glucocorticoids commonly cause drug-induced diabetes. This association is well recognized but available evidence does not answer clinically relevant issues in subjects without diabetes.

18 March 2008 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
MDMelanie J Davies
Melanie J Davies
FLFernando Javier Lavalle-González
Fernando Javier Lavalle-González
FSF. Storms
F. Storms
RGR. Gomis
R. Gomis
AGAT.LANTUS Study Group
AT.LANTUS Study Group
Objective:  For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide optimal glycaemic control, necessitating insulin therapy. Fear of hypoglycaemia is a major barrier to initiating insulin therapy. The AT.LANTUS study investigated optimal methods to initiate and maintain insulin glargine (LANTUS ® , glargine, Sanofi‐aventis, Paris, France) therapy using two treatment algorithms. This subgroup analysis investigated the initiation of once‐daily glargine therapy in patients suboptimally controlled on multiple OADs. Research Design and Methods:  This study was a 24‐week, multinational (59 countries), multicenter (611), randomized study. Algorithm 1 was a clinic‐driven titration and algorithm 2 was a patient‐driven titration. Titration was based on target fasting blood glucose ≤100 mg/dl (≤5.5 mmol/l). Algorithms were compared for incidence of severe hypoglycaemia [requiring assistance and blood glucose <50 mg/dl (1 OAD. Incidence of severe hypoglycaemia was <1%. HbA 1c decreased significantly between baseline and end‐point for patients receiving glargine plus 1 OAD (−1.4%, p < 0.001; algorithm 1 −1.3% vs. algorithm 2 −1.5%; p = 0.03) and glargine plus >1 OAD (−1.7%, p < 0.001; algorithm 1 −1.5% vs. algorithm 2 −1.8%; p = 0.001). Conclusions:  This study shows that initiation of once‐daily glargine with OADs results in significant reduction of HbA 1c with a low risk of hypoglycaemia. The greater reduction in HbA 1c was seen in patients randomized to the patient‐driven algorithm (algorithm 2) on 1 or >1 OAD.

27 November 2014 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
JPJesús Zacarías Villarreal Pérez
Jesús Zacarías Villarreal Pérez
JVJesús Zacarías Villarreal-Martínez
Jesús Zacarías Villarreal-Martínez
FLFernando Javier Lavalle-González
Fernando Javier Lavalle-González
MTMaría del Rosario Torres-Sepúlveda
María del Rosario Torres-Sepúlveda
CRConsuelo Ruiz-Herrera
Consuelo Ruiz-Herrera
LVLaura E. Martínez de Villarreal
Laura E. Martínez de Villarreal
The two primary pathophysiological characteristics of patients with type 2 diabetes mellitus (T2DM) are insulin resistance (IR) and beta cell dysfunction. It has been proposed that the development of IR is secondary to the accumulation of triacylglycerols and fatty acids in the muscle and liver, which is in turn thought to be secondary to an enzymatic defect in mitochondrial beta-oxidation. The purpose of the present study was to analyze the molecules of intermediary metabolism to determine if an alteration in mitochondrial function exists in T2DM patients and, if so, to determine whether this alteration is caused by excess nutrients or an enzymatic defect. Seventy-seven subjects were recruited and divided into four groups (21 T2DM patients, 17 non-diabetic overweight/obese subjects, 20 offspring of T2DM patients, and 19 healthy subjects). Anthropometric parameters were determined by air plethysmography, and biochemical and metabolic parameters were measured, including 31 acylcarnitines (ACs) and 13 amino acids quantified by MS/MS and 67 organic acids measured by GC/MS. Patients with T2DM showed elevation of short-chain ACs (C2, C4), a glycogenic amino acid (valine), a glycogenic and ketogenic amino acid (tyrosine), and a ketogenic amino acid (leucine) as well as altered excretion of dicarboxylic acids. T2DM offspring with abnormal glucose tolerance test GTT showed increased levels of C16. Subjects in the obese group who were dysglycemic also showed altered urinary excretion of dicarboxylic acids and lower levels of a long-chain AC (C14:2). These results suggest that mitochondrial beta-oxidation is altered in T2DM patients and that the alteration is most likely caused by nutrient overload through a different pathway from that observed in obese subjects.

7 September 2009 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
JGJosé Gerardo González‐González
José Gerardo González‐González
LMLeonardo G. Mancillas‐Adame
Leonardo G. Mancillas‐Adame
MFMercedes Fernández‐Reyes
Mercedes Fernández‐Reyes
MGMinerva Gómez‐Flores
Minerva Gómez‐Flores
FLFernando Javier Lavalle-González
Fernando Javier Lavalle-González
JPJesús Zacarías Villarreal Pérez
Jesús Zacarías Villarreal Pérez